Parts One and Two covered the science and the clinical realities. Part Three is about everything the science doesn’t capture: the celebrity confessions, the class divide, the Instagram transformations, the shame, and the genuinely complex ethical questions that a drug this powerful — and this expensive — inevitably raises.
The Room That Knew: Hollywood and the Ozempic Open Secret
It started as a whisper on red carpets, spread as an open secret through award show greenrooms, and exploded into a full cultural reckoning when comedian Nikki Glaser surveyed a room full of dramatically slimmed-down stars at the 2024 Oscars and delivered the line of the night: “It’s Ozempic’s biggest night.” The audience laughed. What else could they do? Half of them were probably the punchline.
A year earlier, Chelsea Handler had hosted the Critics’ Choice Awards and deadpanned that Hollywood’s sudden wave of slimness was powered not by smaller portions but by Ozempic — not fully disclosing at the time that she had tried it herself, having been handed a few doses by a doctor who offered them casually, almost as an afterthought.
Oprah Winfrey chose a more deliberate disclosure. After decades of public weight struggles that made her a target for commentary no human being deserves, she called access to weight-loss medication “relief, like redemption, like a gift” — and challenged anyone who viewed it as cheating to examine the biology they were ignoring. Kathy Bates, Rebel Wilson, Amy Schumer, Whoopi Goldberg, Meghan Trainor, Kelly Clarkson, Serena Williams, Sharon Osbourne — all candid, to varying degrees, about using GLP-1 drugs. Countless others went conspicuously quiet when reporters noted their changing bodies, offering “smaller portions” and “clean living” with a straight face.
Sharon Osbourne’s story became a cautionary note. She lost so much weight she dropped below 100 pounds and couldn’t stop losing. “You can lose so much weight, and it’s easy to become addicted to that, which is very dangerous,” she said. “I couldn’t stop.” Even after stopping the medication, she struggled to regain weight she now wanted back — a real and underacknowledged consequence of the drug’s potency.
The cultural fallout has been measurable. Bariatric surgeries in the US fell nearly 42% between 2019 and 2024. Cosmetic procedures linked to rapid weight loss — thigh lifts, arm lifts — rose sharply. The term “Ozempic face” entered the vernacular to describe the hollowed, gaunt look that can accompany rapid fat loss, though experts are clear: it is the speed of weight loss, not the drug itself, that causes this.
More troubling than any individual story is the broader pattern: people who do not medically qualify obtaining GLP-1 drugs through unregulated channels. Model Lottie Moss obtained Ozempic without a prescription and described having a seizure from dehydration after misuse. In Australia — which has among the highest eating disorder rates in the world — clinicians have raised particular alarm about telehealth prescriptions reaching people with active disordered eating. Psychologist Laura Smolcic, who has worked in eating disorder care for over two decades, warned that GLP-1s risk becoming the newest chapter in a very old story: the belief that thin is inherently better, that getting there justifies the cost, and that the body is always a problem to be solved.
The Ethics of a $1,300-a-Month Breakthrough
The Access Divide
Brand-name GLP-1 medications cost between $1,000 and $1,350 per month in the US without adequate insurance coverage. In Canada, Ozempic and Wegovy run $300–$400 per month — and most public drug plans only cover them for type 2 diabetes. In Australia, private-market users pay $200–$600 per month, with roughly half of all GLP-1 use occurring outside the subsidized system. In the UK, where 95% of users are buying privately at around £150 per month, NHS-funded access is deliberately phased over years due to capacity concerns.
The cruelest irony: the people who need these medications most — those living with severe obesity and its related diseases — are disproportionately in lower-income brackets, where the cost is most prohibitive. Research consistently shows GLP-1 use is lowest among Black, Hispanic, and lower-income populations, despite higher rates of obesity-related disease in these same communities. Without deliberate equity policies, this revolution could deepen existing health disparities rather than address them.
Weight Stigma: Better or Worse?
Some researchers hoped GLP-1s would reduce weight stigma by reframing obesity as a medical condition requiring treatment — not a personal failure deserving judgment. The evidence is ambiguous. Research published in 2025 suggests that rather than reducing stigma, widespread GLP-1 adoption may in some contexts intensify it: if treatment is now available and someone isn’t using it, the old blame reasserts itself in a new form. Social media has simultaneously celebrated dramatic weight-loss results and amplified the cultural pressure to be thin — often with zero acknowledgment of the prescription and monthly price tag behind the transformation.
Eating Disorders and Vulnerable Populations
GLP-1 medications suppress appetite profoundly and rapidly. For people with histories of restrictive eating disorders, this suppression can reinforce dangerous patterns rather than disrupt them. Eating disorder specialists are increasingly advocating for careful screening before prescribing and ongoing monitoring throughout treatment — particularly in Australia, where eating disorder rates are among the highest globally and telehealth prescribing has fewer guardrails.
A Word About Food, Money, and a System Not Built for Everyone
The people reaching for GLP-1 medications are not lazy. Many have spent years doing everything they were told — counting calories, weighing portions, exercising through exhaustion — and still could not make their bodies do what they needed them to do. They were told the problem was their effort. The problem, much of the time, was their biology.
And here is something that almost never enters this conversation: eating well in this world is not an equal opportunity endeavor. Fresh produce, quality proteins, whole grains, and minimally processed foods cost significantly more per calorie than refined carbohydrates — white bread, white pasta, sugar, ultra-processed snack foods. A bag of pasta costs a dollar. Salmon costs fifteen. In many food deserts across North America, Australia, and the UK, a candy bar is cheaper and more accessible than an apple. The people who face the greatest barriers to a nutrient-dense diet are often the same people carrying the highest rates of metabolic disease — and the same people least able to afford the medications that could help them.
This is not a personal failing. It is a systemic one. A gut health dietitian working in this space knows that food is not just nutrition — it is culture, comfort, memory, accessibility, and identity. The best support holds all of that gently while helping someone build the strongest possible foundation for their health.
The medication can open a door that felt permanently locked. What matters is what gets built in the room beyond it — and that no one has to build it alone.
Here is the part that almost no one is talking about — not the celebrities, not the prescribers, and certainly not the headlines. GLP-1 medications borrow the language of your gut. They mimic a hormone your own digestive system already makes. Which means the health of your gut determines how well this whole system works — and what happens when the medication eventually changes. In Part Four, I show you exactly what is happening in your microbiome, why it matters more than you have been told, and what a gut health dietitian does that no prescription can replicate.
Ready to have a real conversation about your health — without judgment?
References
Jensen SD, Gualano B, Andreassen P, et al. Beyond the prescription: global observations on the social implications of GLP-1 receptor agonists for weight loss. PLoS Glob Public Health. 2025;5(12):e0005516. doi:10.1371/journal.pgph.0005516
Beyond weight loss: GLP-1 usage and appetite regulation in the context of eating disorders. Nutrients. 2025;17(23):3735. doi:10.3390/nu17233735
Ethical issues related to the use of GLP-1 receptor agonists. Bioethics. 2025. doi:10.1111/bioe.70068
The societal implications of using GLP-1 receptor agonists for the treatment of obesity. EClinicalMedicine. 2025. doi:10.1016/j.eclinm.2025.103021
Health Policy Partnership. Are weight-loss treatments contributing to health inequalities? March 2025. Accessed May 4, 2026. https://www.healthpolicypartnership.com
Pan XH, et al. The GLP-1 RA boom: trends in Australia, 2020–2025. medRxiv. 2025. doi:10.1101/2025.10.30.25339120
Kantar. GLP-1 agonists: the next big disruptor in society. August 2025. Accessed May 4, 2026. https://www.kantar.com/uki/inspiration/fmcg/2025-wp-glp-1-agonists
Leger Healthcare. GLP-1 survey of Canadians and Americans. February 2026. Referenced in CBC News. Accessed May 4, 2026. https://www.cbc.ca/news/health/canadians-glp1-ozempic-mounjaro-9.7114197